Tissue Regenix Group (TRX)

 

TRX Share PerformanceMore

52 week high22.500 18/03/16
52 week low12.700 18/01/16
52 week change 2.250 (15.00%)
4 week volume5,040,425 07/11/16

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Tissue Regenix issues OrthoPureT XT update

Tissue Regenix Group said the early clinical data provided to support the CE mark application for OrthoPure XT (porcine ...

OrthoPureT XT update

RNS Number: 2655Q Tissue Regenix Group PLC 28 November 2016 Tissue Regenix Group plc OrthoPure XT update - Early patient outcomes show statistically significant improvement over gold standard procedure - First European distributors appointed Leeds, 28 November 2016 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative...

Tissue Regenix says CFO Ian Jefferson to depart

Tissue Regenix said chief financial officer Ian Jefferson has notified the Board of his intention to leave the Company. He w...

Directorate Change

RNS Number: 7426P Tissue Regenix Group PLC 22 November 2016 Tissue Regenix Group plc Directorate Change Leeds, 22November 2016 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Company") the regenerative medical devices company announces Chief Financial Officer, Ian Jefferson, has notified the Board of his intention to leave the Company...

Tissue Regenix widens H1 pretax loss

Tissue Regenix has widened its H1 pretax loss to 5.4m, from a year-earlier loss of 4.0m. Revenue was just 631,000, from 252,0...

Interim Results

RNS Number: 2812M Tissue Regenix Group PLC 12 October 2016 Tissue Regenix Group plc ("Tissue Regenix" or "the Group") Unaudited Interim Results for the six months ended 31 July 2016 Leeds, 12 th October 2016 - Tissue Regenix Group (AIM:TRX) "Tissue Regenix" or "The Group", the regenerative medical devices company, today announces its unaudited interim...

Notice of Interim Results

RNS Number: 0087L Tissue Regenix Group PLC 28 September 2016 Tissue Regenix Group plc Notice of Interim Results Leeds, 28 September 2016 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company today gives notice that it will announce its interim results for the six months ending 31 July 2016, on Wednes...

Edison research outlook on Tissue Regenix

Edison has issued research outlook on Tissue Regenix. It says: "Tissue Regenix's (TRX) investment story is built on dCELL, ...

Fundamental DataMore

EPS-1.27
Dividend yield0 %

Equity Research (TRX)

edison investment research
Tissue Regenix Group Plc
19/10/2016
Tissue Regenix’s interim results are in line with our expectations and demonstrate the progress the company is making to achieve various milestones in each of its divisions. In particular, its Wound...
edison investment research
Tissue Regenix Group Plc
28/07/2016
Tissue Regenix’s (TRX) investment story is built on dCELL, a versatile regenerative medical technology, and its potential across the subsectors: wound care, orthopaedics and cardiac implants....
edison investment research
Tissue Regenix Group Plc
22/03/2016
Tissue Regenix’s (TRX’s) investment case is built on dCELL, a patented decellularised tissue scaffold. Wound care is a main driver for TRX’s growth and recent announcements demonstrate progress on...

Latest discussion posts More

Users' HoldingsMore

Users who hold Tissue Regenix Group also hold..
LLOYDS GRP.30%
TESCO23%
SIRIUS MINERALS23%
BP23%
ID:ISIN:GB00BD8GDH8621%

Codes & Symbols

ISINGB00B5SGVL29
SymbolsTRX, LSE:TRX, TRX.L, TRX:LN, LON:TRX, XLON:TRX